About Fibrobiologics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://fibrobiologics.com/
Frequently Asked Questions
What is the 52-week range for FBLG?
The 52-week high is $11.4 and the 52-week low is $0.62.
What is the P/E ratio for FBLG?
The P/E ratio data is currently unavailable.
What is the dividend yield for FBLG?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -536.78%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.43.
Analyst Recommendation Trends
Wall Street analyst consensus for FBLG over the last few months:
Latest FBLG News
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Anbio Biotechnology (NASDAQ:NNNN) stock moved upwards by 16.9% to $6.49 during Friday's after-market session. The market value of their outstanding shares is at $276.0 million. Stablecoin Development
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Patent No. 3568465, titled "Methods of Enhancing Fibroblast Therapeutic Activity." The patent covers methods of augmenting the efficacy of fi
FibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic Activity
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 26, at 7:00 p.
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases September 22, 2026 4:15 PM...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose 39.21% to
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of a private placement on September 15, 2026, with Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, for the purchase of 298,508 shares of common stock and accompanying
FibroBiologics Completes ATM Private Placement Of 298,508 Shares And Warrants At $1.675 Per Unit To Its Chief Scientific Officer
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an overview of FibroBiologics' strategy to develop off-the-shelf fibroblast-based cell therapies for chronic diseases and regenerative medicine. The Company is advancing a platform designed to harness the regenerative and immune-modulating properties of fibroblasts across multiple indications, including chronic wound care, psoriasis, multiple sclerosis, degenerative disc disease, and thymus regeneration.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Khoja Hamid | +298,508 | - | - |
| 2026-09-15 | Khoja Hamid | +298,508 | $1.675 | $500,001 |
| 2026-06-23 | Cilento Richard C. Jr. | +30,803 | - | - |
| 2026-06-23 | Niklas Victoria Ninon Olivia | +30,803 | - | - |
| 2026-06-23 | Link Matthew | +30,803 | - | - |
| 2026-06-23 | Hoffman Robert E. | +30,803 | - | - |
| 2026-05-04 | Khoja Hamid | +61,607 | - | - |
| 2026-05-04 | GARCIA RUBEN A | +61,607 | - | - |
| 2026-05-04 | O'HEERON PETE | +92,410 | - | - |
| 2026-05-04 | Davis Jason | +61,607 | - | - |
| 2026-03-04 | Khoja Hamid | +30,000 | $0.38 | $11,400 |
| 2026-03-04 | O'HEERON PETE | +15,872 | $0.3784 | $6,006 |
| 2026-03-03 | O'HEERON PETE | +18,200 | $0.4051 | $7,373 |
| 2026-03-02 | O'HEERON PETE | +17,428 | $0.353 | $6,152 |
| 2026-03-02 | Davis Jason | +70,000 | $0.4139 | $28,973 |
| 2026-02-27 | GARCIA RUBEN A | +40,000 | $0.3264 | $13,056 |
| 2025-12-11 | GARCIA RUBEN A | +140,000 | $0.34 | $47,600 |